ADHD (Attention Deficit / Hyperactive Disorder) is a disorder that makes it difficult for a person to pay attention and control impulsive behaviors. He or she may also be restless and almost constantly active.
Do you find it hard to pay attention? You feel the need to move constantly during times when you shouldn’t? Do you find yourself constantly interrupting others?
If these issues arrive its more likely that you are suffering fro ADHD. Probably consult with a proper doctor before starting any form of medication. ADHD starts early on any childhood and may carry on into adulthood. The causes of ADHD vary;
Adolescents and young adults being treated for ADHD may be at a higher risk of having a psychotic event if they are provided amphetamine medicines, such as Adderall and Vyvanse, instead of medications based on the compound methylphenidate, such as Ritalin or Concerta, according to a study published.
Psychosis is a symptom, not an illness. A mental or physical illness, substance abuse, or extreme stress or trauma can cause it. Psychotic disorders, like schizophrenia, are mental illnesses that involve psychosis that usually happens for the first time in the late teen years or early adulthood.
The study is unlikely to affect which medications are used in most cases, but it could lead doctors to look more carefully at potential risk factors for other mental illnesses when they prescribe medicines for ADHD. The method by which the data were collected is also noteworthy: Researchers used “real-world evidence,” a term that refers to data collected in the course of medical practice, not in the gold-standard of randomized, controlled clinical trials.
Schneeweiss said in an interview that Aetion was founded because of “a huge demand for real-world evidence that comes close to causal conclusions” and that such an effort, which required well-paid software engineers, couldn’t have come together within Harvard. The company is working with the Food and Drug Administration to see if its databases can replicate the results of randomized trials, which randomly assign patients to one treatment or another. Aetion’s software platform, he said, is “transparent with audit trails with all the bells and whistles that regulators are requiring to make regulatory decisions based on these studies.” Aetion has raised a total of $77 million from investors including McKesson Ventures, Sanofi, and UCB, according to Pitchbook.
The next step, Moran and Schneeweiss said, will be to conduct further studies to help doctors identify which patients might be more at risk of a psychotic episode.